NCT03411941View on ClinicalTrials.gov

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

CompletedOBSERVATIONAL
Enrollment

116

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

March 1, 2019

Study Completion Date

March 1, 2019

Conditions
Macular Degeneration
Interventions
DRUG

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

IVT(Intravitreal) aflibercept treatment in routine clinical practice.

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY